{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Rajendra A"],"journal":["Blood cancer journal"],"pagination":["143"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12378385"],"repository":["biostudies-literature"],"pubmed_title":["Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis."],"pmcid":["PMC12378385"],"pubmed_authors":["Rajendra A","Davidson MB","Gupta V","Schimmer AD","Perusini MA","Richard-Carpentier G","Smith E","Atenafu EG","Tang K","Yee K","Schuh AC","Maze D","Minden MD","Sibai H","Bankar A","Chan S"],"additional_accession":[]},"is_claimable":false,"name":"Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.","description":null,"dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-10T01:48:51.461Z","creation":"2026-04-08T01:25:00.605Z"},"accession":"S-EPMC12378385","cross_references":{"pubmed":["40854875"],"doi":["10.1038/s41408-025-01353-2"]}}